By: Saparja Nag  Apr. 24, 2018

The EkoSonic™ Endovascular system, produced by EKOS of BTG Interventional Medicine, is an innovative treatment for venous thromboembolism (VTE). It combines ultrasound technology and traditional thrombolytic medicines to more efficiently dissolve blood clots. More information as to how this unique system works can be found in a previous article about EKOS. One of the most prevalent comorbidities of VTE is infectious disease, as they share similar pathways of coagulation, inflammatory processes, and fibrinolysis processes. In infectious disease, these biological responses are caused both by the pathogens themselves and by the immune system’s response. Inflammation’s effects on hemostasis can often lead to thrombosis, presenting a serious risk for patients with infections.

By: Saparja Nag  Apr. 10, 2018

The EKOS system, by BTG Interventional Medicine, offers an innovative treatment option for patients with pulmonary embolisms by combining thrombolytic medicines and ultrasound waves to dissolve blood clots. The EkoSonic™ Endovascular system utilizes Acoustic Pulse Thrombolysis™ to target and thin fibrin in order to dissolve a blood clot, which occurs by making the fibrin more porous and creating a pressure gradient to deliver the thrombolytics deeper within the clot. This therapeutic system offers multiple benefits over other venous thromboembolism (VTE) interventions including lowered risk of bleeding and other complications by targeting the clot specifically without affecting surrounding vessels, valves, or walls, and lower dosage requirements compared to both catheter-directed drug delivery and traditional systemic delivery via the circulatory system. The use of the EkoSonic™ Endovascular system provides a number of advantages over more traditional treatment options of VTE and thus may significantly affect mortality rates for certain conditions.